Yujiro Hata - Mar 2, 2023 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Director
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Mar 2, 2023
Transactions value $
$0
Form type
4
Date filed
3/6/2023, 04:18 PM
Previous filing
Feb 28, 2023
Next filing
Apr 13, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (right to buy) Award $0 +10.8K $0.00 10.8K Mar 2, 2023 Common Stock 10.8K $47.72 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2023), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2024 annual meeting of stockholders.